<DOC>
	<DOCNO>NCT00892749</DOCNO>
	<brief_summary>This multi-center , open-labeled , non-comparative study examine safety efficacy ASP1585 long-term dosing chronic kidney disease hyperphosphatemia patient hemodialysis .</brief_summary>
	<brief_title>Long-term Study Patients With Chronic Kidney Disease Hyperphosphatemia Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Chronic kidney disease patient hemodialysis Hyperphosphatemia Written inform consent Patients gastrointestinal surgery enterectomy Severe cardiac disease patient Patients severe constipation diarrhea Patients complication malignant tumor Patients uncontrolled hypertension Patients treat parathyroid intervention</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>hyperphosphatemia</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>CKD</keyword>
	<keyword>ASP1585</keyword>
</DOC>